BioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by 2030

Rhea-AI Summary

BioNTech (Nasdaq: BNTX) announced that co-founders Prof. Ugur Sahin and Prof. Özlem Türeci will form an independent company to develop next-generation mRNA innovations, with BioNTech contributing related rights and technologies for a minority stake and possible milestones/royalties.

A binding agreement is expected by end H1/2026, founders will transition to the new company by end 2026, and BioNTech expects 15 ongoing Phase 3 oncology trials and multiple late-stage readouts in 2026.

Positive

• BioNTech expects 15 Phase 3 oncology trials by year-end 2026
• Founders to create a new company with dedicated mRNA focus
• BioNTech to receive a minority stake plus milestones and royalties

Negative

• Cofounders will transition out of BioNTech management by end of 2026
• Details of the transaction remain conditional until a binding agreement is signed

News Market Reaction – BNTX

-17.88% 5.3x vol

52 alerts

-17.88% News Effect

-18.7% Trough in 3 hr 6 min

-$5.76B Valuation Impact

$26.46B Market Cap

5.3x Rel. Volume

On the day this news was published, BNTX declined 17.88%, reflecting a significant negative market reaction. Argus tracked a trough of -18.7% from its starting point during tracking. Our momentum scanner triggered 52 alerts that day, indicating high trading interest and price volatility. This price movement removed approximately $5.76B from the company's valuation, bringing the market cap to $26.46B at that time. Trading volume was exceptionally heavy at 5.3x the daily average, suggesting significant selling pressure.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Phase 3 trials: 15 trials Management transition date: End of 2026 Agreement timing: End of H1 2026 +3 more

6 metrics

Phase 3 trials 15 trials Expected ongoing oncology Phase 3 clinical trials by year-end 2026

Management transition date End of 2026 Founders plan to transition to new company management roles

Agreement timing End of H1 2026 Target timing to sign binding agreements for the new company

Company age 18 years Time building BioNTech from start-up to global biopharmaceutical company

Founders’ biotech companies Third company New venture follows Ganymed Pharmaceuticals (2001) and BioNTech (2008)

Multi-product target year 2030 Stated goal to become a commercial multi-product company by 2030

Market Reality Check

Price: $91.28 Vol: Volume 953,127 vs 20-day ...

high vol

$91.28 Last Close

Volume Volume 953,127 vs 20-day average 619,923 (relative volume 1.54), indicating elevated trading interest pre-announcement. high

Technical Shares at $102.31, trading below the 200-day MA of $104.86 despite a strategic narrative about building a multi-product portfolio by 2030.

Peers on Argus

BNTX moved higher by 0.65% with elevated volume, while key biotech peers like IN...

BNTX moved higher by 0.65% with elevated volume, while key biotech peers like INSM (+2.47%), GMAB (+2.60%), INCY (+1.21%), RPRX (+0.95%) and ONC (+3.17%) also traded up, but no peers appeared in the momentum scanner, pointing to a company-specific driver.

Historical Context

5 past events · Latest: Feb 24 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 24	Earnings timing	Neutral	+0.9%	Announcement of Q4 and full-year 2025 results date and investor call.
Jan 28	Management change	Positive	-2.7%	Appointment of Chief People Officer to support multi-product strategy by 2030.
Jan 12	Strategic update	Positive	+2.3%	Outlined 2026 priorities, 15 Phase 3 trials and strong cash and guidance.
Dec 18	Acquisition close	Positive	-0.1%	Completion of CureVac acquisition to strengthen mRNA capabilities.
Dec 09	Clinical data	Positive	-1.5%	Encouraging Phase 2 pumitamig data in advanced triple-negative breast cancer.

Pattern Detected

Recent news has mostly been strategic or clinical and generally met with modest price reactions, with both positive and negative moves following ostensibly positive updates.

Recent Company History

Over the past six months, BioNTech news has centered on strategy, management, clinical progress, and M&A. A December 2025 CureVac acquisition closing and positive Phase 2 pumitamig data in TNBC underscored its mRNA and oncology ambitions. The January 2026 J.P. Morgan update highlighted expectations for 15 Phase 3 trials and multiple late-stage readouts, supported by a strong cash position. Management-building steps, like appointing a Chief People Officer, align with the goal of becoming a multi-product oncology company by 2030. Today’s founder-led spin-out and focus on next-generation mRNA fits this strategic arc.

Market Pulse Summary

The stock dropped -17.9% in the session following this news. A negative reaction despite the constru...

Analysis

The stock dropped -17.9% in the session following this news. A negative reaction despite the constructive framing would fit prior instances where positive strategic or clinical news was followed by weak price performance, such as the pumitamig Phase 2 update. The announcement involves founders transitioning to a separate company by end of 2026 while BioNTech targets 15 Phase 3 trials and multi-product status by 2030. Concerns could center on leadership transition risk and uncertainty around value capture from the minority stake and future milestones and royalties.

Key Terms

immunomodulator, antibody-drug conjugate, adc, mrna, +4 more

8 terms

immunomodulator medical

"growing late-stage clinical pipeline spanning immunomodulator, ADC and mRNA candidates"

An immunomodulator is a medicine or therapy that changes how the immune system behaves—either boosting its ability to fight infections and cancer or calming it to reduce harmful inflammation. Investors watch these products because their success in clinical trials, safety and side-effect profiles, and regulatory approvals can open large markets or limit sales; think of them as tools that tweak the body’s defense system, with outcomes that strongly affect a drug maker’s future revenue and stock value.

antibody-drug conjugate medical

"late-stage clinical pipeline spanning immunomodulator, antibody-drug conjugate (“ADC”) and mRNA"

An antibody-drug conjugate is a targeted medicine that combines an antibody, which can identify specific cells, with a powerful drug designed to destroy those cells. This approach allows for precise treatment, minimizing damage to healthy tissue. For investors, developments in this area can signal advances in cancer therapies and potential growth opportunities in the biotech sector.

adc medical

"late-stage clinical pipeline spanning immunomodulator, antibody-drug conjugate (“ADC”) and mRNA"

An antibody-drug conjugate (ADC) is a targeted cancer medicine that pairs an antibody that recognizes specific markers on tumor cells with a potent cell-killing drug, connected so the toxic payload is delivered directly to the cancer. For investors, ADCs matter because successful ADCs can improve patient outcomes and reduce side effects compared with traditional chemotherapy, shaping clinical trial success, regulatory approval chances, commercial demand, and a company’s valuation much like a guided missile versus a general bomb.

mrna medical

"biotechnology company to research and develop next-generation mRNA innovations"

mRNA, short for messenger ribonucleic acid, is a biological molecule that carries instructions from a cell’s genetic blueprint to make specific proteins — like a recipe or software code that tells a kitchen or computer what to produce. Investors care because mRNA is used as a flexible drug and vaccine platform that can be developed and scaled faster than many traditional medicines; its commercial prospects, manufacturing needs, regulatory approval path, and patent position can strongly affect a company’s value.

phase 3 clinical trials medical

"BioNTech expects to have 15 ongoing Phase 3 clinical trials in oncology by year end"

Phase 3 clinical trials are large, late-stage studies that test a drug or medical treatment in hundreds to thousands of patients to confirm it is safe and effective and to compare it with existing options. Investors care because positive results are a key step toward regulatory approval and commercial sales, reducing uncertainty much like a full dress rehearsal before a product launch; negative results can sharply reduce a program’s value.

minority stake financial

"technologies to the new company in exchange for a minority stake"

An ownership share in a company that is less than 50%, so the holder cannot unilaterally control management or major decisions. It matters to investors because a minority stake lets you share in profits, dividends and upside if the company grows, but limits your ability to influence strategy or protect your interests; think of it like owning a slice of a pie—you benefit from the taste and value, but you don’t decide how the whole pie is made.

milestones financial

"in exchange for a minority stake and other forms of consideration such as milestones and royalties"

Milestones are specific, measurable progress points a company aims to reach during a project—like completing a clinical trial step, securing a regulatory approval, or hitting a sales target. They matter to investors because each checkpoint reduces uncertainty about the business plan, can trigger payments or changes in valuation, and often signals whether future revenue or growth is likely, similar to passing checkpoints on a racecourse that show how close you are to the finish line.

royalties financial

"in exchange for a minority stake and other forms of consideration such as milestones and royalties"

Payments made to the owner of an asset or intellectual property each time that asset is used or a product is sold, often calculated as a percentage of sales or a set amount per unit. Royalties matter to investors because they create predictable, ongoing income streams and affect a company’s cash flow and valuation—like a landlord collecting rent or an author getting a steady cut whenever a book is sold.

AI-generated analysis. Not financial advice.

• BioNTech continues to sharpen its strategic focus on the growing late-stage clinical pipeline spanning immunomodulator, ADC and mRNA candidates
• BioNTech co-founders Ugur Sahin and Özlem Türeci will establish an independent biotechnology company to research and develop next-generation mRNA innovations; management transition by end of 2026
• Both companies focus on distinct strategic priorities to maximize value for patients and shareholders, with BioNTech planning to contribute related rights and mRNA technologies to the new company in exchange for a minority stake
• Signing of binding agreements expected by end of H1/2026

Mainz, Germany, March 10, 2026 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced plans for an independent company to be established and led by BioNTech co-founders Prof. Ugur Sahin, M.D., and Prof. Özlem Türeci, M.D. The new company with distinct resources, operations and funding options, will advance next-generation mRNA innovations. BioNTech plans to contribute related rights and mRNA technologies to the new company to enable and support the prioritized development of next-generation mRNA innovations with disruptive potential. With both companies focusing on their respective strategic priorities, BioNTech expects to maximize value for patients and shareholders alike.

BioNTech is sharpening its strategic focus on the development and commercialization of its growing late-stage pipeline spanning innovative immunomodulator, antibody-drug conjugate (“ADC”) and mRNA candidates. Its current clinical pipeline, including previously announced milestones and the COVID-19 vaccine franchise, remains unaffected by the plans for the new company: BioNTech expects to have 15 ongoing Phase 3 clinical trials in oncology by year end. 2026 will also be the first year in which the Company expects multiple late-stage data readouts across major cancer types. The clinical trials and resulting data will inform regulatory and launch plans.

Ugur Sahin and Özlem Türeci will transition into the management of their new company by the end of 2026 after their current service agreements end. BioNTech’s Supervisory Board has initiated an executive search to identify successors for the positions to ensure a smooth transition and seamless execution of BioNTech’s strategy.

“Over the past 18 years, we have built BioNTech from a start-up into a global biopharmaceutical company with a strong and diversified pipeline. During the COVID-19 pandemic, we expanded beyond oncology to develop the first approved mRNA vaccine, helping to protect people worldwide. Today, the company is well positioned to advance its mission and evolve into a commercial multi-product company. None of this would have been possible without the extraordinary dedication of our teams, the trust of our shareholders and Supervisory Board, and the commitment of the partners who have supported us along the way. For us, this is the right time to prepare to hand over the baton,” said Prof. Ugur Sahin, M.D., Chief Executive Officer and Co-Founder of BioNTech. “At the same time, Özlem and I are ready to become pioneers once again. Our vision has always been to translate our science into meaningful advances for patients, and we see extraordinary opportunities to unlock the next generation of transformative innovations.”

“Over the course of their careers, Ugur and Özlem have established an outstanding track record of innovation. As BioNTech advances multiple late-stage product candidates towards commercialization, we support them in taking the opportunity to apply their strengths and undivided attention to a new venture, dedicated to enabling mRNA-based technologies to reach their full potential,” said Helmut Jeggle, Chairman of the BioNTech Supervisory Board. “We believe that this plan will be additive for both, BioNTech and the new company, as it aims to allow each organization to drive meaningful impact for patients. We look forward to working together with their new company on potential combination therapy approaches, setting the stage for continued success.”

BioNTech co-founders and mRNA technology pioneers Prof. Ugur Sahin, M.D., and Prof. Özlem Türeci, M.D., will establish their third biotechnology company following the foundation of Ganymed Pharmaceuticals in 2001 and BioNTech in 2008. As a next-generation mRNA company, it is aimed at pioneering cutting-edge platform technologies and advancing the research and development of mRNA-based innovations with disruptive potential. To this end, BioNTech plans to contribute related rights and mRNA technologies to the new company on an arm’s length basis in exchange for a minority stake and other forms of consideration such as milestones and royalties. It aims to benefit both companies by providing them with opportunities to collaborate on combination approaches involving their respective product candidates, with the potential to create new complementary or synergistic treatment strategies. A binding agreement is expected to be signed by the end of the first half of 2026 after which further details will be communicated by BioNTech.

About BioNTech
Biopharmaceutical New Technologies (BioNTech) is a global next generation immunotherapy company pioneering novel investigative therapies for cancer and other serious diseases. BioNTech exploits a wide array of computational discovery and therapeutic modalities with the intent of rapid development of novel biopharmaceuticals. Its diversified portfolio of oncology product candidates aiming to address the full continuum of cancer includes mRNA cancer immunotherapies, next-generation immunomodulators and targeted therapies such as antibody-drug conjugates (ADCs) and innovative chimeric antigen receptor (CAR) T cell therapies. Based on its deep expertise in mRNA development and in-house manufacturing capabilities, BioNTech and its collaborators are researching and developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global and specialized pharmaceutical collaborators, including Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech, a member of the Roche Group, Genmab, MediLink, OncoC4, Pfizer and Regeneron.

For more information, please visit www.BioNTech.com.

BioNTech Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: expected changes to BioNTech’s leadership and the transition of responsibilities at the Management Board, including identification and recruitment of successors; the terms of the preliminary discussions between BioNTech and the co-founders, including the potential contribution of certain BioNTech assets to an independent company and the form of consideration payable to BioNTech; the timing for execution of definitive agreements between BioNTech and the co-founders; the companies’ ability to collaborate on combination approaches for their product candidates; BioNTech’s research and development programs, including its expectations regarding initiations of clinical trials; BioNTech’s focus on building commercial capabilities for potential market launches; and BioNTech’s expectations regarding the timing of, ability to obtain and maintain regulatory approval of, and planned readiness for, such launches. In some cases, forward-looking statements can be identified by terminology such as “will,” “may,” “should,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors, many of which are beyond BioNTech’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to: BioNTech’s ability to reach definitive agreements with its co-founders; discussions with regulatory agencies regarding timing and requirements for additional clinical trials; the ability to produce comparable clinical results in future clinical trials; competition related to BioNTech’s product candidates, including those with different mechanisms of action and different manufacturing and distribution constraints, on the basis of, among other things, efficacy, cost, convenience of storage and distribution, breadth of approved use, side-effect profile and durability of immune response; the timing of and BioNTech’s ability to obtain and maintain regulatory approval for BioNTech’s product candidates; BioNTech’s and its counterparties’ ability to manage and source necessary resources; BioNTech’s ability to identify research opportunities and discover and develop investigational medicines; the ability and willingness of BioNTech’s third-party collaborators to continue research and development activities relating to BioNTech’s development candidates and investigational medicines; BioNTech’s and its collaborators’ ability to commercialize and market its product candidates, if approved; BioNTech’s ability to manage its development and expansion; regulatory developments in the United States and other countries and regions; BioNTech’s ability to effectively scale its production capabilities and manufacture its product candidates; and other factors not known to BioNTech at this time.

You should review the risks and uncertainties described under the heading “Risk Factors” in BioNTech’s Report on Form 6-K for the period ended December 31, 2025 and in subsequent filings made by BioNTech with the SEC, which are available on the SEC’s website at www.sec.gov. These forward-looking statements speak only as of the date hereof. Except as required by law, BioNTech disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise.

CONTACTS

Media Relations
Jasmina Alatovic
Media@biontech.de

Investor Relations
Douglas Maffei, PhD
Investors@biontech.de

FAQ

What will BioNTech (BNTX) contribute to the new co‑founders‑led company?

BioNTech will contribute related rights and mRNA technologies in exchange for a minority stake and consideration. According to the company, consideration may include milestones and royalties to support the new company's development.

When will the binding agreements between BioNTech (BNTX) and the new company be signed?

A binding agreement is expected by the end of the first half of 2026. According to the company, further transaction details will be communicated after the agreement is signed.

When will BioNTech co‑founders leave management to lead the new mRNA company?

Prof. Ugur Sahin and Prof. Özlem Türeci will transition to the new company's management by the end of 2026. According to the company, their current service agreements run until that transition.

How does this plan affect BioNTech's (BNTX) current clinical pipeline?

BioNTech says the current clinical pipeline, milestones and COVID‑19 vaccine franchise remain unaffected by the plan. According to the company, development and commercialization of late‑stage programs will continue as prioritized.

What near‑term clinical expectations did BioNTech (BNTX) announce for 2026?

BioNTech expects to have 15 ongoing Phase 3 oncology trials and multiple late‑stage data readouts in 2026. According to the company, those readouts will inform regulatory and launch plans.